Pki-166

Pki-166

SCHEMBL9973098

C[C@H](Nc1ncnc2[nH]c(-c3ccc(O)cc3)cc12)c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

EGFR

The experimentally established mechanism targets of Pki-166. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
EGFR known ✓ P00533 19/20 1.00
CSF1R P07333 1/20 0.78
HDAC3 O15379 1/20 0.74
KDR P35968 1/20 0.74
HDAC4 P56524 1/20 0.74
HDAC1 Q13547 1/20 0.74
HDAC7 Q8WUI4 1/20 0.74
HDAC2 Q92769 1/20 0.74
HDAC10 Q969S8 1/20 0.74
HDAC11 Q96DB2 1/20 0.74
HDAC8 Q9BY41 1/20 0.74
HDAC6 Q9UBN7 1/20 0.74
HDAC9 Q9UKV0 1/20 0.74
HDAC5 Q9UQL6 1/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pki-166 SCHEMBL185822 1.00 EGFR (1.00) EGFRCSF1RHDAC3KDRHDAC4
Pki-166 SCHEMBL30883827 1.00 EGFR (1.00) EGFRCSF1RHDAC3KDRHDAC4
Pki-166 SCHEMBL29352405 1.00 EGFR (1.00) EGFRCSF1RHDAC3KDRHDAC4
Pki-166 SCHEMBL209560 1.00 EGFR (1.00) EGFRCSF1RHDAC3KDRHDAC4
Pki-166 SCHEMBL29409570 0.99 EGFR (0.98) EGFRCSF1RHDAC3KDRHDAC4
SCHEMBL12308303 0.89 EGFR (0.86) EGFRCSF1RHDAC3KDRHDAC4
SCHEMBL4766235 0.89 EGFR (0.86) EGFRCSF1RHDAC3KDRHDAC4
SCHEMBL4766237 0.89 EGFR (0.86) EGFRCSF1RHDAC3KDRHDAC4
SCHEMBL7499430 0.89 EGFR (0.86) EGFRCSF1RHDAC3KDRHDAC4
SCHEMBL4901987 0.89 EGFR (1.00) EGFRHDAC3KDRHDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130204238-A1 COMBINATION THERAPY FOLLICA, INC (US) 2013-08-08 US disclosed
US-20130204238-A1 COMBINATION THERAPY FOLLICA, INC (US) 2013-08-08 US disclosed
US-8252749-B2 Methods, kits, and compositions for generating new hair follicles and growing hair FOLLICA, INC. (US) 2012-08-28 US disclosed
US-8252749-B2 Methods, kits, and compositions for generating new hair follicles and growing hair FOLLICA, INC. (US) 2012-08-28 US disclosed
US-20120156228-A1 Methods, Kits, and Compositions for Generating New Hair Follicles and Growing Hair FOLLICA, INC. (US) 2012-06-21 US disclosed
US-20120156228-A1 Methods, Kits, and Compositions for Generating New Hair Follicles and Growing Hair FOLLICA, INC. (US) 2012-06-21 US disclosed
US-20110130706-A1 SEQUENTIAL BODY SURFACE TREATMENT FOLLICA, INC. (US) 2011-06-02 US disclosed
US-20110130706-A1 SEQUENTIAL BODY SURFACE TREATMENT FOLLICA, INC. (US) 2011-06-02 US disclosed
US-20110130711-A1 HAIR GROWTH TREATMENT FOLLICA, INC. (US) 2011-06-02 US disclosed
US-20110130711-A1 HAIR GROWTH TREATMENT FOLLICA, INC. (US) 2011-06-02 US disclosed
US-20110130748-A1 BODY SURFACE TREATMENT FOLLICA, INC. (US) 2011-06-02 US disclosed
US-20110130748-A1 BODY SURFACE TREATMENT FOLLICA, INC. (US) 2011-06-02 US disclosed
US-20100298760-A1 METHODS, KITS, AND COMPOSITIONS FOR ADMINISTERING PHARMACEUTICAL COMPOUNDS PURETECH VENTURES 2010-11-25 US disclosed
US-20100298760-A1 METHODS, KITS, AND COMPOSITIONS FOR ADMINISTERING PHARMACEUTICAL COMPOUNDS PURETECH VENTURES 2010-11-25 US disclosed
US-20100120768-A1 METHODS, KITS, AND COMPOSITIONS FOR GENERATING NEW HAIR FOLLICLES AND GROWING HAIR LIGHTHOUSE CAPITAL PARTNERS VI, L.P. 2010-05-13 US disclosed
US-20100120768-A1 METHODS, KITS, AND COMPOSITIONS FOR GENERATING NEW HAIR FOLLICLES AND GROWING HAIR LIGHTHOUSE CAPITAL PARTNERS VI, L.P. 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120768-A1 METHODS, KITS, AND COMPOSITIONS FOR GENERATING NEW HAIR FOLLICLES AND GROWING HAIR NGF, HDGF, SHH EGFR 85/4885CSF1R 1717/4885HDAC3 2419/4885
US-20120156228-A1 Methods, Kits, and Compositions for Generating New Hair Follicles and Growing Hair NGF, HDGF, SHH EGFR 85/4885CSF1R 1717/4885HDAC3 2419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.